Biopharmaceuticals Pipeline Glycotope’s mature biopharmaceuticals pipeline Find out more
Biopharmaceuticals Services Glycotope’s unique development expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company and experienced leadership
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
Gatipotuzumab
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
30. Jul
2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Tokyo, Berlin, Basking Ridge, NJ – (July 30, 2018) – Daiichi Sankyo Company, Limited […]

18. Jul
2018
DCprime and Glycotope announce licensing agreement and collaboration

Leiden, The Netherlands, and Berlin, Germany, 18 July 2018 – DCprime BV, a clinical […]

See All News
Events
18-22 Mar
2019
CHI’s Immuno-Oncology Summit Europe
25-27 Mar
2019
Bio-Europe Spring
See All Events